Famitinib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Nasopharyngeal Carcinoma
Conditions
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma
Trial Timeline
Jul 1, 2011 → Aug 1, 2016
NCT ID
NCT01392235About Famitinib
Famitinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Recurrent Nasopharyngeal Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01392235. Target conditions include Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma.
What happened to similar drugs?
4 of 20 similar drugs in Recurrent Nasopharyngeal Carcinoma were approved
Approved (4) Terminated (0) Active (16)
🔄Nivolumab + Gemcitabine + Cisplatin + Carboplatin + Paclitaxel + PemetrexedOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05473468 | Phase 1 | UNKNOWN |
| NCT04479904 | Phase 2 | Withdrawn |
| NCT01762293 | Phase 2 | Completed |
| NCT02336724 | Phase 2 | UNKNOWN |
| NCT01994213 | Phase 2 | Terminated |
| NCT01392235 | Phase 2 | Completed |
Competing Products
20 competing products in Recurrent Nasopharyngeal Carcinoma